DSM-Firmenich AG: reports H1-2024 Fiancial Results

Kaiseraugst (CH) | Heerlen (NL). (dsf) DSM-Firmenich AG reports its financial results for the first half 2024. Cief Executive Officer Dimitri de Vreeze: «We are pleased with our achievements in the first six months of the year. We launched our strategic plan at our capital markets day in June and are making good progress with the synergies and vitamin transformation programs. The separation of the Animal Nutrition and Health business is well underway, and we announced two divestments as part of our portfolio fine-tuning.

«Our relentless focus on operational excellence, combined with improving business conditions, resulted in better financial results. Perfumery and Beauty and Taste, Texture and Health both delivered a strong performance. Health, Nutrition and Care and Animal Nutrition and Health saw improved momentum.

«We upgrade our full year outlook to around EUR 2 billion based on the positive business momentum continuing into the third quarter and our commitment to deliver a EUR 200 million Adjusted Ebitda contribution from a combination of synergy delivery and the vitamin transformation program, while we should remain cautious about the general economic conditions in which our customers operate.»

Outlook: The company increases its outlook and expects an Adjusted Ebitda of around EUR 2 billion in FY 2024. For additional information please read the Company’s PDF file below (464 KB):

20240816-DSM-FIRMENICH-H12024.